High dose intravenous immune globulins and plasma exchange in Guillain-Barré Syndrome.
We report the effects of treatment with plasma-exchange (PE) and intravenous immune globulins (IVIg) in 36 out of 50 patients with Guillain-Barré syndrome (GBS) recruited by an incidence study in the Emilia-Romagna region of Italy. Comparison of the patients treated with PE and IVIg showed no significant differences in terms of effectiveness in improving the clinical course of GBS: at one month, respectively 11.1% and 25% had recovered, and 55.5% and 58.3% had improved by at least one grade. These results are in agreement with those of the Dutch GBS trial. No relapses were observed in either group. Moreover, our results showed no difference in clinical outcome at 1 and 3 months between the patients receiving only one therapy and those receiving two; a second cycle of therapy did not seem to improve the clinical course of the disease significantly. We conclude that PE and IVIg are both safe and effective therapies for GBS.
Ravasio
A
A
Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology, Italy.
Pasquinelli
M
M
Currò Dossi
B
B
Neri
W
W
Guidi
C
C
Gessaroli
M
M
Rasi
F
F
Fabbri
R
R
Mazzini
G
G
Rebucci
G G
GG
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010951:Plasma Exchange; D011129:Polyradiculoneuropathy / Q000628:therapy*; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous